SEC Form 4 · accession 0001694665-18-000008
Evelo Biosciences, Inc. · EVLO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Char
Officer — General Counsel
Period of report
Oct 31, 2018
Accepted (ET)
Nov 1, 2018 · 4:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001694665
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $9.11 | Oct 31, 2018 | A | 100,000 | A | — | Oct 30, 2028 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The option vests and becomes exercisable as to 25% of the total grant on October 29, 2019 and vests in equal quarterly installments over a three year period thereafter